2025 is set to change the industry. The new administration is poised to challenge many existing processes. The question is whether they will be based on data-driven analysis or ideologies and beliefs.
Our guests address this concern along with the existing challenges CEOs face, particularly manufacturing processes.
Additionally, they discuss weight loss drugs, focusing on GLP-1s, with medical precision.
Host
Lori Ellis, Head of Insights, BioSpace
Guests
Miguel Forte, President, International Society for Cell & Gene Therapy; Board Member, ARM; CEO and Board Member, Kiji Therapeutics
Ali Pashazadeh, Founder, Treehill Partners
